KMDA.TA

Kamada Ltd. [KMDA.TA] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

KMDA.TA Stock Summary

Earnings have grown 10.19% per last year.

EPS has increased from the previous year and become positive (Yearly statements)

Earnings are expected to fall -100% next year

Profit margins (0.04%) are lower than the previous year (0.06%)

KMDA.TA has less than 1 year of cash runway

An RSI reading of 30 or below indicates an oversold or undervalued condition.

Top 10 Correlated ETFs

KMDA.TA

Top 10 Correlated Stocks

KMDA.TA

In the News

KMDA.TA Financial details

Company Rating

Buy

Market Cap

1.11B

Income

8.28M

Revenue

142.52M

Book val./share

Cash/share

Dividend

Dividend %

Employees

378

Optionable

Shortable

Yes

Earnings

14 May 2024

P/E

44.37

Forward P/E

PEG

-1.89

P/S

2.26

P/B

1.15

P/C

P/FCF

194.26

Quick Ratio

2.13

Current Ratio

4.11

Debt / Equity

0.04

LT Debt / Equity

0.03

EPS (TTM)

0.07

EPS next Y

EPS next Q

EPS this Y

-428.19%

EPS next Y

EPS next 5Y

EPS last 5Y

-20.93%

Revenue last 5Y

2.3%

Revenue Q/Q

-3.96%

EPS Q/Q

SMA20

-7.22%

SMA50

-6.53%

SMA100

10.32%

Inst Own

Inst Trans

ROA

ROE

ROC

0.04%

Gross Margin

37%

Oper. Margin

Profit Margin

Payout

Shs Outstand

Shs Float

Target Price

52W Range

1627.0-2329.0

52W High

-19.11%

52W Low

+15.8%

RSI

29.01

Rel Volume

2.71

Avg Volume

37.86K

Volume

102.55K

Perf Week

-5.14%

Perf Month

-18.58%

Perf Quarter

11.15%

Perf Half Y

-0.42%

Beta

0.243

Volatility

30.3%, 76.73%

Prev Close

-1.62%

Price

1884

Change

-3.88%

KMDA.TA Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	3.15	3.03	2.31	2.89	2.66
Net income per share	0.55	0.39	-0.05	-0.05	0.15
Operating cash flow per share	0.68	0.43	-0.2	0.64	0.08
Free cash flow per share	0.63	0.31	-0.28	0.55	-0.03
Cash per share	1.83	2.49	0.42	0.76	1.04
Book value per share	3.36	4.06	3.95	3.93	4.55
Tangible book value per share	3.35	4.03	0.52	0.65	1.94
Share holders equity per share	3.36	4.06	3.95	3.93	4.55
Interest debt per share	0.15	0.12	0.57	0.48	0.19
Market cap	275.84M	282.18M	296.39M	183.79M	328.88M
Enterprise value	238.93M	216.92M	302.15M	170.13M	282.06M
P/E ratio	12.4	16.46	-132.91	-79.19	39.7
Price to sales ratio	2.17	2.12	2.86	1.42	2.31
POCF ratio	10	14.77	-33.61	6.43	76.22
PFCF ratio	10.92	20.72	-23.62	7.41	-214.25
P/B Ratio	2.04	1.58	1.68	1.04	1.35
PTB ratio	2.04	1.58	1.68	1.04	1.35
EV to sales	1.88	1.63	2.92	1.32	1.98
Enterprise value over EBITDA	8.4	8.62	58.02	16.18	12.6
EV to operating cash flow	8.67	11.35	-34.26	5.95	65.37
EV to free cash flow	9.45	15.93	-24.08	6.86	-183.75
Earnings yield	0.08	0.06	-0.01	-0.01	0.03
Free cash flow yield	0.09	0.05	-0.04	0.13	0
Debt to equity	0.04	0.03	0.14	0.12	0.04
Debt to assets	0.03	0.02	0.08	0.06	0.02
Net debt to EBITDA	-1.3	-2.59	1.11	-1.3	-2.09
Current ratio	4.39	7.13	2.41	1.84	3.43
Interest coverage	77.76	72.32	-0.55	4.96	7.75
Income quality	1.24	1.11	3.95	-12.32	0.52
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0.07	0.08	0.12	0.1	0.13
Research and developement to revenue	0.1	0.1	0.11	0.1	0.1
Intangibles to total assets	0	0.01	0.48	0.46	0.39
Capex to operating cash flow	-0.08	-0.29	0.42	-0.13	-1.36
Capex to revenue	-0.02	-0.04	-0.04	-0.03	-0.04
Capex to depreciation	-0.51	-1.12	-0.67	-0.31	-0.46
Stock based compensation to revenue	0.01	0.01	0.01	0.01	0.01
Graham number	6.46	5.97	2.1	2.14	3.97
ROIC	0.15	0.09	0	0.02	0.04
Return on tangible assets	0.13	0.08	-0.01	-0.01	0.04
Graham Net	1.91	2.69	-1.26	-1.13	0.09
Working capital	110.82M	152.95M	75.99M	63.3M	120.37M
Tangible asset value	135.02M	177.15M	23.16M	28.95M	104.07M
Net current asset value	105.08M	145.89M	-11.8M	-7.35M	59.08M
Invested capital	0.04	0.03	0.14	0.12	0.04
Average receivables	28.73M	26.56M	35.33M	40M	28.63M
Average payables	21.06M	20.47M	20.61M	29.01M	28.86M
Average inventory	36.24M	42.59M	54.72M	68.1M	78.63M
Days sales outstanding	76	72.95	155.08	101.49	54.52
Days payables outstanding	117.02	68.62	124.98	145.39	104.03
Days of inventory on hand	203.46	178.96	335.67	303.82	371.08
Receivables turnover	4.8	5	2.35	3.6	6.69
Payables turnover	3.12	5.32	2.92	2.51	3.51
Inventory turnover	1.79	2.04	1.09	1.2	0.98
ROE	0.16	0.1	-0.01	-0.01	0.03
Capex per share	-0.06	-0.12	-0.08	-0.08	-0.11

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric	2022-12-31	2023-03-31	2023-06-30	2023-09-30	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	1.08	0.68	0.84	0.71	0
Net income per share	0.07	-0.04	0.04	0.06	0
Operating cash flow per share	0.16	-0.06	0.04	0.02	0
Free cash flow per share	0.14	-0.09	0.02	-0.02	0
Cash per share	0.81	0.6	0.49	0.98	0
Book value per share	4.19	3.9	3.94	4.44	0
Tangible book value per share	0.69	3.9	3.94	4.44	0
Share holders equity per share	4.19	3.9	3.94	4.44	0
Interest debt per share	0.5	0.52	0.48	0.12	0
Market cap	172.48M	210.44M	236.97M	287.29M	0
Enterprise value	158.82M	206.04M	236.4M	240.55M	-46.82M
P/E ratio	14.65	-29.08	32.69	22.28	0
Price to sales ratio	3.8	6.85	6.33	7.57	0
POCF ratio	25.58	-73.81	130.35	311.94	0
PFCF ratio	29.92	-53.03	307.75	-355.56	0
P/B Ratio	0.98	1.2	1.34	1.21	0
PTB ratio	0.98	1.2	1.34	1.21	0
EV to sales	3.5	6.71	6.31	6.34	-1.29
Enterprise value over EBITDA	23.54	122.94	42.78	38.03	-5.29
EV to operating cash flow	23.56	-72.27	130.03	261.18	-10.62
EV to free cash flow	27.55	-51.93	307.01	-297.71	-19.22
Earnings yield	0.02	-0.01	0.01	0.01	0
Free cash flow yield	0.03	-0.02	0	0	0
Debt to equity	0.12	0.13	0.12	0.02	0.04
Debt to assets	0.06	0.07	0.07	0.02	0.02
Net debt to EBITDA	-2.02	-2.62	-0.1	-7.39	-5.29
Current ratio	1.84	1.9	1.97	4.11	3.43
Interest coverage	12.14	0.58	5.99	10.81	-61.69
Income quality	2.29	1.58	1	0.29	0.87
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0.07	0.11	0.09	0.1	0.21
Research and developement to revenue	0.07	0.11	0.11	0.08	0.09
Intangibles to total assets	0.46	0.46	0.46	0.42	0.39
Capex to operating cash flow	-0.14	0.39	-0.58	-1.88	-0.45
Capex to revenue	-0.02	-0.04	-0.03	-0.05	-0.05
Capex to depreciation	-0.32	-0.36	-0.33	-0.54	-0.62
Stock based compensation to revenue	0	0.01	0.01	0.01	0.01
Graham number	2.57	1.88	1.89	2.45	0
ROIC	0.02	0	0.01	0.02	0.01
Return on tangible assets	0.02	-0.01	0.01	0.02	0.02
Graham Net	-1.21	-1.26	-1.23	0.2	0
Working capital	63.3M	62.13M	63.86M	115.88M	120.37M
Tangible asset value	28.95M	29.5M	32.77M	95.89M	104.07M
Net current asset value	-7.35M	-10.58M	-7.95M	54.49M	59.08M
Invested capital	0.12	0.13	0.12	0.02	0.04
Average receivables	33.42M	30.25M	26.09M	27.21M	24.02M
Average payables	31.77M	29.56M	27.09M	20.39M	18.81M
Average inventory	70.91M	74.27M	80M	77.02M	81.14M
Days sales outstanding	71.23	71.88	66.48	63.48	52.59
Days payables outstanding	98.27	125	109.41	49.85	101.38
Days of inventory on hand	205.34	380.36	313.88	287.13	361.63
Receivables turnover	1.26	1.25	1.35	1.42	1.71
Payables turnover	0.92	0.72	0.82	1.81	0.89
Inventory turnover	0.44	0.24	0.29	0.31	0.25
ROE	0.02	-0.01	0.01	0.01	0.02
Capex per share	-0.02	-0.02	-0.02	-0.03	0

KMDA.TA Frequently Asked Questions

What is Kamada Ltd. stock symbol ?

Kamada Ltd. is a IL stock and trading under the symbol KMDA.TA

What is Kamada Ltd. stock quote today ?

Kamada Ltd. stock price is $1884 today.

Is Kamada Ltd. stock public?

Yes, Kamada Ltd. is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 37.86K
Market Capitalization 1.11B
Employee 378
CEO Mr. Amir London
Headquarters Rehovot,IL
IPO Date 2005-08-31
Website https://www.kamada.com

Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD. It also provides KamRho (D) IM for prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN for Allergic rhinitis and Urticaria; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for cytomegalovirus virus; RUCONEST for angioedema attacks; heparin sodium injection for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. Further, it offers IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis ; and ELIGARD for prostate cancer. The company markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Takeda Pharmaceuticals Company Limited; PARI GmbH; and Kedrion Biopharma. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.